Answer

Mr Wheeler is referring to the antibody therapy lecanemab, which hit the headlines towards the end of 2022 when a clinical trial discovered the drug’s ability to slow cognitive decline in patients with early onset Alzheimer’s.

Lecanemab was found to break down clumps of a protein called beta amyloid, thought to be a key cause of dementia, in patient’s brains. Published in The New England Journal of Medicine, the clinical trial indicated that the drug slowed the decline in mental agility by 27 per cent over 18 months.